The ITC complaint builds on the patent infringement suit filed in federal district court on May 12, 2026, and is based on Nanomics' infringement of U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, which protect Seer's intellectual property in the field of nanoparticle protein enrichment. Seer's ITC complaint seeks institution of an investigation into Nanomics' importation and sale of its Proteonano kits and workstations, and an exclusion order barring those products from entering the United States.
"Seer pioneered the technology and advanced the science that makes it possible to pursue deep, unbiased proteomics at scale, catalyzing large data sets that will drive AI-enabled biological discoveries. We have an obligation to ensure that this technology delivers the most robust and reproducible data for our customers," said Omid Farokhzad, Chair and Chief Executive Officer of Seer. "Filing this ITC complaint, alongside our district court action, reflects our resolve to use every available avenue to protect our technology, innovations, and product integrity that have defined this field and that our customers rely on every day."